Stoke Therapeutics (NASDAQ:STOK) vs. Invivyd (NASDAQ:IVVD) Head to Head Contrast

Invivyd (NASDAQ:IVVD) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Volatility and Risk

Invivyd has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.

Insider and Institutional Ownership

70.4% of Invivyd shares are held by institutional investors. 12.2% of Invivyd shares are held by company insiders. Comparatively, 9.6% of Stoke Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Invivyd and Stoke Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
Stoke Therapeutics	-753.60%	-59.36%	-51.46%

Earnings & Valuation

This table compares Invivyd and Stoke Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43 million	5.15	-$52.49 million	($0.33)	-2.83
Stoke Therapeutics	$184.42 million	10.00	-$6.89 million	($3.34)	-8.56

Stoke Therapeutics has higher revenue and earnings than Invivyd. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Invivyd and Stoke Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1	2	3	0	2.33
Stoke Therapeutics	1	0	10	0	2.82

Invivyd currently has a consensus price target of $8.00, suggesting a potential upside of 757.45%. Stoke Therapeutics has a consensus price target of $44.25, suggesting a potential upside of 54.84%. Given Invivyd’s higher possible upside, equities research analysts plainly believe Invivyd is more favorable than Stoke Therapeutics.

About Invivyd

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

About Stoke Therapeutics

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.